OPKO Health (NASDAQ: OPK) saw its stock price plummet 5.47% in after-hours trading on Thursday following the release of its second quarter 2025 financial results. The healthcare company reported widening losses and missed revenue expectations, disappointing investors despite beating earnings per share estimates.

For Q2 2025, OPKO Health reported an adjusted loss of $0.07 per share, which was better than the analyst consensus estimate of a $0.11 loss. However, the company's quarterly revenue came in at $156.8 million, falling short of the expected $165.744 million and representing a 13.94% decrease from the same period last year when the company reported sales of $182.2 million.

The company's financial position deteriorated significantly year-over-year, with a reported net loss of $148.4 million for the quarter, compared to a much smaller loss in the previous year. Operating income also took a hit, coming in at negative $60 million. Despite these challenges, OPKO's board authorized an additional $100 million for stock repurchases, potentially signaling confidence in the company's long-term prospects. However, this move did little to assuage investor concerns in the face of the disappointing quarterly results.